Table 1.

Clinical, biochemical, pathological features and follow up after resection in 73 patients with malignant IPMT according to their pathological status (in situ or invasive carcinoma)

	In situ (n=22)	Invasive (n=51)	p Value
Sex (male/female)	14/8	35/16	NS
Median age (y)	62.6 (25–89)	63.8 (38–81)	NS
First symptom
Acute pancreatitis	8	12	NS
Abdominal pain	4	9	NS
Jaundice	2	10	NS
Diarrhoea	3	6	NS
Weight loss	2	6	NS
Diabetes	2	2	NS
Mass	0	2	NS
Asymptomatic	1	4	NS
Median diagnosis delay (months)	24 (0–196)	3 (0–180)	0.01
CEA (n=38)* ≥2N	0/12	6/26	NS
CA 19.9 (n=46)* ≥2N	1/12	16/34	0.03
Tumour location
Head/corpus	14	35	NS
Tail	2	12	NS
Diffuse	4	2	NS
Duct involvement
Main duct or combined	18	47	NS
Branch ducts only	4	4	NS
Median tumour size (mm) (n=60)*	23 (9–40)	36 (10–130)	0.01
Pancreatic cut surface
Normal	17	33	NS
Simple hyperplasia	2	7	NS
Atypical hyperplasia	1	6	NS
In situ carcinoma	2	2	NS
Invasive carcinoma	0	3	NS
Metastatic lymph nodes	0	17	0.002
Cancer relapse	0	28	0.001
Median follow up (months)	28 (0–145)	23 (0–115)	NS
Postoperative death	1	2	NS
Five year survival (SE)	88% ( 8)	36% ( 9)	0.001

IPMT, intraductal papillary mucinous tumours of the pancreas; CEA, carcinoembryonic antigen; CA 19.9, carbohydrate antigen 19-9; NS, p>0.05. N, upper limit of the normal laboratory value. *Available data.